MedPath

Omnitura Therapeutics, Inc.

Omnitura Therapeutics, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2001-01-01
Employees
-
Market Cap
-
Website
http://www.omnitura.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance

Withdrawn
Conditions
Prostate Cancer
Interventions
First Posted Date
2018-04-12
Last Posted Date
2021-10-18
Lead Sponsor
Omnitura Therapeutics, Inc.
Registration Number
NCT03495479

A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: Aneustat (OMN54)
First Posted Date
2012-03-15
Last Posted Date
2015-04-08
Lead Sponsor
Omnitura Therapeutics, Inc.
Target Recruit Count
22
Registration Number
NCT01555242
Locations
🇨🇦

BC Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.